Infistar Renewables Pvt. Ltd. entered into an exclusive joint venture with Finland’s Arciplug Oy to manufacture factory-built modular plug-flow reactors for small-scale Compressed Biogas (CBG) plants in India. The partnership aims to capitalise on the rapidly growing demand for green fuels as India accelerates the expansion of its domestic biogas production capacity under its clean energy and circular economy initiatives.

Joint Venture to Focus on Modular CBG Technology

The joint venture, Arcistar Bioenergy Pvt. Ltd., will manufacture advanced modular plug-flow reactor systems designed specifically for small CBG plants. These factory-built modular units are expected to simplify plant installation, reduce project timelines and improve operational efficiency, making compressed biogas production more accessible for small and medium-sized developers.

₹50 Crore Investment for Demonstration Project

As part of the initial phase, the joint venture will invest approximately ₹50 crore to establish a demonstration project in Gandhinagar district, Gujarat. The facility will showcase the technology and serve as a reference plant before the companies expand commercial deployment across India. Arcistar Bioenergy plans to market its modular reactors for compressed biogas plants with methane production capacities of less than three tonnes per day. By focusing on this underserved segment, the company aims to provide cost-effective and scalable technology solutions that support decentralised biogas production while enhancing operational efficiency.

Addressing India’s Growing CBG Market

India’s Compressed Biogas (CBG) market, currently valued at approximately ₹8,000–9,000 crore, is witnessing strong growth, driven by increasing investments in renewable energy, sustainable waste management and the Government’s clean fuel initiatives. The partnership between Infistar Renewables and Arciplug is well positioned to tap this expanding market by offering innovative reactor technology that can accelerate the development of smaller CBG projects across the country.

Supporting India’s Green Energy Transition

The joint venture reflects the growing collaboration between Indian and international technology companies to advance sustainable energy solutions. As reported by thehindubusinessline.com, by combining Infistar’s local market expertise with Arciplug’s advanced reactor technology, Arcistar Bioenergy aims to strengthen India’s compressed biogas ecosystem, promote indigenous green fuel production and contribute to the country’s long-term renewable energy and carbon reduction goals.

Sun Pharmaceutical Industries Limited signed a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at an enterprise value of US$11.75 billion. Under the agreement, Sun Pharma will acquire all outstanding shares of Organon. The acquisition is expected to significantly strengthen Sun Pharma’s global presence across innovative medicines, women’s healthcare, branded generics and biosimilars, while expanding its footprint in key international markets.

Strategic Acquisition to Accelerate Global Growth

The proposed acquisition aligns with Sun Pharma’s long-term strategy of expanding its Innovative Medicines business and reinforcing its leadership in the Established Brands and Branded Generics segment. The transaction will enable Sun Pharma to enter the rapidly growing biosimilars market as one of the Top 10 global players. By integrating Organon’s portfolio, manufacturing capabilities and international commercial network, the company aims to accelerate sustainable growth and create long-term value for stakeholders.

Organon Brings Strong Global Portfolio

Organon was established in 2021 following its spin-off from Merck & Co., Inc. (known as MSD outside the United States and Canada). Today, the company operates as a global healthcare leader with a strong focus on women’s health. Its portfolio comprises more than 70 products spanning women’s health, general medicines and biosimilars, which are commercialised in over 140 countries. Organon’s largest markets include the United States, Europe, China, Canada and Brazil. The company also operates six manufacturing facilities across the European Union and emerging markets, providing a robust manufacturing and supply chain platform.

Enhancing Sun Pharma’s Global Healthcare Leadership

With the addition of Organon, Sun Pharma expects to strengthen its diversified healthcare portfolio while expanding access to high-quality medicines worldwide. The acquisition will combine Organon’s strong global brands, customer relationships and healthcare expertise with Sun Pharma’s manufacturing excellence, research capabilities and global commercial network. Together, the combined organisation aims to improve healthcare access, strengthen affordability and deliver innovative treatment solutions across multiple therapeutic segments.

A Transformational Opportunity

Dilip Shanghvi, Executive Chairman of Sun Pharma, said, “The transaction represents a significant opportunity for Sun Pharma to build on its vision of ‘Reaching People and Touching Lives’. Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe bringing the two organisations together will create a stronger and more diversified platform. We have deep respect for Organon’s mission and look forward to building on its legacy while driving sustainable long-term growth.”

Kirti Ganorkar, Managing Director of Sun Pharma, described the acquisition as a strategic milestone in the company’s global expansion. “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products. Our immediate priorities will be business continuity, disciplined integration and responsible value creation. We also see significant opportunities to leverage Organon’s talented workforce while unlocking meaningful revenue synergies over the coming years,” Ganorkar mentioned.

Organon Board Supports the Transaction

Carrie Cox, Executive Chair of Organon, said the agreement delivers immediate value to shareholders while ensuring long-term continuity for the company’s business. “Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders. We believe Sun Pharma is well positioned to support Organon’s businesses, employees and patients globally, while continuing our commitment to delivering impactful medicines and healthcare solutions,” Cox said.

Expanding Global Footprint and Future Opportunities

The acquisition positions Sun Pharma to significantly strengthen its global healthcare business by expanding its presence in women’s health, biosimilars, innovative medicines and branded generics. As per the press release, Organon’s established international footprint, diversified product portfolio and manufacturing infrastructure are expected to complement Sun Pharma’s existing strengths. The combined company is well positioned to accelerate innovation, expand market reach and create sustainable long-term value for patients, healthcare providers, investors and other stakeholders worldwide.

Aether Industries Ltd. and Dow Chemical International Pvt. Ltd. (Dow India) entered into a strategic research partnership to develop advanced silicone manufacturing technologies in India. The collaboration aims to strengthen indigenous innovation, enhance domestic manufacturing capabilities and support the country’s growing demand for high-performance silicone materials.

Joint Research Programme to Boost Indigenous Technology

Under the partnership, Aether Industries and Dow India will jointly develop next-generation manufacturing technologies for silicones. The initiative is expected to reduce India’s dependence on imported technologies while creating a strong foundation for future commercial production within the country. By combining their technical expertise, the two companies aim to accelerate innovation and contribute to the growth of India’s specialty chemicals and advanced materials sector.

Research to Be Conducted at Surat Facility

The joint research programme will be carried out at Aether Industries’ research and pilot facilities in Surat, Gujarat. Initially, both companies will focus on research and development, process optimisation and pilot-scale testing. Subsequently, they will evaluate opportunities to scale up the technologies for commercial manufacturing.

Building a Long-Term Strategic Partnership

Beyond research, the agreement establishes the framework for a long-term strategic collaboration between Aether Industries and Dow India. The partnership also opens the door for the commercialisation and industrial-scale production of the silicone manufacturing technologies developed under the programme, subject to successful research outcomes.

Leveraging Complementary Expertise

Dr. Aman Desai, Co-Founder and Director (Research and Operations), Aether Industries, said the company is delighted to partner with Dow India as its exclusive research collaborator for the programme. He noted that Aether’s strong capabilities in chemistry, process development and manufacturing technology, combined with Dow’s global expertise in silicone materials and applications, will help develop innovative manufacturing technologies tailored to India’s growing market requirements.

Supporting India’s Growing Silicone Industry

Silicones are high-performance materials widely used across industries such as construction, transportation, electronics, healthcare and personal care. By developing advanced silicone manufacturing technologies within India, the collaboration is expected to strengthen the domestic supply chain, encourage technological self-reliance and support the expansion of India’s specialty chemicals industry. As reported by angelone.in, the partnership also aligns with the country’s broader vision of promoting innovation-driven manufacturing and building globally competitive capabilities in advanced materials.

GAIL (India) Limited, one of India’s leading integrated energy company, has been included in the globally recognised FTSE4Good Index Series, marking a significant milestone in its environmental, social and governance (ESG) journey. Following the June 2026 review conducted by FTSE Russell, GAIL received the FTSE4Good Index Certificate of Membership, recognising its strong commitment to sustainable business practices and responsible corporate governance.

Recognition Highlights Strong ESG Performance

The inclusion in the FTSE4Good Index Series reflects GAIL’s consistent efforts to uphold high standards of Environmental, Social and Governance (ESG) performance. The company continues to strengthen its sustainability initiatives by promoting environmental stewardship, enhancing social responsibility and maintaining robust corporate governance practices. Consequently, GAIL has aligned its ESG strategy with globally accepted sustainability standards and investor expectations.

FTSE4Good Index: A Global ESG Benchmark

The FTSE4Good Index Series is one of the world’s leading sustainable investment indices. It evaluates and recognises companies that demonstrate strong ESG performance based on internationally accepted criteria. By securing a place in the index, GAIL joins a select group of global companies that meet rigorous ESG standards, further enhancing its credibility among investors, stakeholders and the global business community.

Strengthening Investor Confidence

GAIL’s inclusion in the FTSE4Good Index Series reinforces its commitment to sustainable value creation and responsible business practices. As reported by msn.com, the recognition is expected to strengthen investor confidence, improve the company’s global ESG profile and support its long-term sustainability goals as it continues to play a key role in India’s evolving energy landscape.

Oil and Natural Gas Corporation Limited (ONGC) appointed Prashant Singh as the Chief Executive Officer (CEO) of ONGC Green Limited, reinforcing the company’s leadership team as it accelerates its renewable energy expansion and clean energy transition. The appointment underscores ONGC’s commitment to building a strong green energy business while advancing its long-term sustainability and net-zero goals.

Industry Veteran to Lead ONGC Green’s Growth Strategy

Prashant Singh brings more than three decades of experience in India’s energy sector. As CEO of ONGC Green Limited, he will spearhead the company’s strategic initiatives to expand its renewable energy portfolio and strengthen its position in the country’s rapidly evolving clean energy landscape. With his extensive industry expertise, Singh is expected to play a pivotal role in driving business growth, fostering innovation and supporting ONGC’s transition towards a low-carbon future.

Strong Track Record in New Energy Initiatives

Before assuming his new role, Singh served as Group General Manager and Head – New Energy at ONGC. During his tenure, he played a key role in shaping and implementing the company’s new energy strategy. He successfully led initiatives aimed at diversifying ONGC’s business beyond conventional oil and gas operations while increasing investments in renewable energy and other sustainable technologies.

Extensive Leadership Across India’s Energy Sector

Apart from his responsibilities at ONGC, Singh serves as a Board Member of Ayana Renewable Power and Pawan Hans Ltd. His leadership experience spans multiple segments of the energy industry, including renewable energy, energy transformation, operational excellence, project execution and strategic business development. This diverse experience is expected to strengthen ONGC Green’s efforts to build a competitive and future-ready clean energy business.

ONGC Green Expands Renewable Energy Portfolio

Singh’s appointment comes at a crucial time as ONGC Green Limited continues to expand its footprint in India’s renewable energy sector. The company is actively pursuing opportunities across solar power, wind energy, green hydrogen and other clean energy technologies. These initiatives align with ONGC’s long-term strategy to support India’s energy transition, contribute to the nation’s net-zero ambitions and meet the growing demand for sustainable energy solutions.

Driving India’s Clean Energy Future

With Prashant Singh at the helm, ONGC Green is well-positioned to accelerate its renewable energy growth strategy. As reported by thebatterymagazine.com, his leadership is expected to strengthen the company’s clean energy portfolio, drive strategic investments and reinforce ONGC’s vision of becoming a leading player in India’s rapidly expanding green energy ecosystem.

Navin Fluorine International Ltd. entered into a strategic partnership with the Defence Research and Development Organisation (DRDO) to develop indigenous manufacturing technology for sodium borohydride, a critical chemical used in defence applications. The collaboration marks a significant step towards strengthening India’s self-reliance in defence chemicals under the Government’s Make in India initiative.

DRDO Awards Project Under Technology Development Fund

As part of the collaboration, DRDO awarded Navin Fluorine a project under its Technology Development Fund (TDF) Scheme to develop the indigenous bulk manufacturing technology for sodium borohydride. The project aims to reduce India’s dependence on imports by establishing domestic production capabilities for this strategically important defence chemical. In addition, DRDO will provide both grant-in-aid funding and technical support to help the company successfully develop and commercialise the technology.

Boosting India’s Defence Manufacturing Ecosystem

Sodium borohydride is a vital chemical with applications in defence and other strategic sectors. By developing indigenous manufacturing capabilities, the project will enhance supply chain security, strengthen domestic manufacturing and support India’s long-term defence preparedness. The initiative aligns with the government’s vision of promoting indigenous technologies and building a robust defence manufacturing ecosystem.

Navin Fluorine Reaffirms Commitment to ‘Make in India’

On the collaboration, Navin Fluorine said, “We take immense pride in our collaboration with DRDO – Ministry of Defence and in contributing towards the Government of India’s ‘Make in India’ initiative.” DRDO stated, “Strengthening India’s indigenous defence capabilities, the Technology Development Fund (TDF) Scheme has awarded a project on ‘Indigenous Manufacturing of Sodium Borohydride Chemical in Bulk’ to M/s Navin Fluorine International Limited. DRDO will provide grant-in-aid and technological support to the industry for developing this technology.”

Advancing Self-Reliance in Strategic Chemicals

The partnership between Navin Fluorine and DRDO underscores India’s growing focus on developing critical defence chemicals through indigenous innovation. As reported by financialexpress.com, once successfully implemented, the project is expected to enhance domestic manufacturing capabilities, reduce import dependence and contribute to the nation’s strategic and technological self-reliance.

Aarti Industries Limited (AIL), one of India’s leading global speciality chemical manufacturers, has announced a major leadership transition as part of its long-term succession strategy. The move reinforces the company’s commitment to stronger corporate governance, institutional leadership and sustainable growth while preserving the entrepreneurial vision that has shaped its success for more than four decades.

Suyog Kotecha Appointed Managing Director & CEO

The Board of Directors approved the appointment of Suyog Kotecha, currently Chief Executive Officer and Executive Director, as the Managing Director & Chief Executive Officer of Aarti Industries. His appointment will take effect from October 1, 2026, subject to shareholders’ approval. At the same time, the Board has approved the transition of the company’s promoter Executive Directors into Non-Executive leadership roles. This change, also effective from October 1, 2026, will further strengthen Aarti Industries’ governance framework while ensuring continuity in strategic decision-making.

Leadership Transition Reflects Long-Term Succession Planning

According to the company, the transition is the outcome of a carefully planned succession process designed to build a professionally managed institution with strong governance practices. The executive management team will oversee day-to-day business operations, while the promoter leadership will continue to provide strategic guidance, industry expertise and long-term vision. As a result, Aarti Industries aims to enhance operational excellence while maintaining the entrepreneurial values that have driven its growth over the years.

Suyog Kotecha to Lead the Next Growth Phase

Since joining Aarti Industries as Chief Executive Officer in June 2024, Suyog Kotecha has played a key role in strengthening the company’s strategic execution. He has focused on expanding customer engagement, enhancing organisational capabilities and driving long-term business growth. Recognising his leadership and contributions, the Board has unanimously expressed confidence in his ability to lead Aarti Industries into its next phase of growth.

Chairman Rajendra Gogri: Planned Succession Strengthens the Institution

Rajendra Gogri, Chairman and Managing Director, said, “For over four decades, Aarti Industries has been built on strong values, technological excellence and enduring customer relationships. This leadership transition reflects our belief in strengthening the institution through planned succession, robust governance and empowered leadership. Over the past two years, Suyog has earned the confidence of the Board through his leadership, strategic perspective and commitment to the company’s values. We are confident that he will lead the Company with the same spirit of excellence, responsibility and customer focus that has defined Aarti Industries for over four decades.”

Rashesh Gogri: A Natural Progression for Aarti Industries

Rashesh Gogri, Managing Director and Vice-Chairman, described the transition as a natural evolution in the company’s journey. “This strategic transition represents the natural progression of Aarti Industries’ legacy. Throughout our history, we have built a strong organisation by investing in people, strengthening technical capabilities and nurturing long-term customer partnerships. We remain fully committed to the company’s long-term success and look forward to providing strategic oversight as Suyog and the executive management team build on this strong foundation.”

Renil Gogri Reaffirms Commitment to Innovation

Renil Gogri, Executive Director and Vice-Chairman, highlighted the company’s long-term vision. “Aarti Industries has always believed in looking beyond the present and investing in the future. As we enter this new chapter, we remain committed to building a globally competitive organisation driven by innovation, guided by purpose and focused on creating sustainable value for our customers, shareholders, employees and the wider community,” Gogri said.

Suyog Kotecha: Focus on Global Competitiveness and Sustainable Growth

Suyog Kotecha, CEO & Managing Director-designate, said, “I am honoured by the trust and confidence placed in me by the Board and the promoter leadership. Aarti Industries has built an exceptional legacy through its talented people, strong customer partnerships, technology leadership and commitment to responsible growth. Together with our Board, leadership team and employees, we will continue to strengthen our global competitiveness, deepen customer relationships and create sustainable long-term value for all stakeholders.”

Strengthening Governance for Future Growth

With this leadership transition, Aarti Industries takes another significant step towards becoming a professionally managed global speciality chemicals company. As reported by ptinews.com, by combining experienced strategic oversight with empowered executive leadership, the company aims to enhance governance standards, accelerate growth, drive innovation and deliver long-term value for customers, shareholders and all stakeholders.

Novartis India Ltd is set to enter a new phase of growth following the acquisition of the Swiss parent company’s 70.68% stake by private equity firm ChrysCapital. The transaction marks a significant ownership transition, paving the way for the company to adopt a new corporate identity, appoint a new leadership team and strengthen its presence in India’s branded pharmaceuticals market. The acquisition follows Novartis AG’s decision in 2024 to review the future of its India-listed subsidiary. Announced earlier this year, the deal was valued at ₹1,446 crore.

ChrysCapital Makes First Majority Investment in Indian Pharma

With this acquisition, ChrysCapital has made its first majority-controlled investment in India’s pharmaceutical sector. The private equity firm said Novartis India will adopt a new name and corporate identity, reflecting its transition from the Swiss pharmaceutical group to an independently managed company backed by private equity. ChrysCapital aims to transform the business into a leading branded generics platform for the Indian pharmaceutical market while building on the company’s strong legacy and established market presence.

New Leadership Team to Drive Next Growth Phase

As part of the ownership transition, Novartis India has appointed Dr. Vikas Gupta as Chief Executive Officer and Managing Director. The company has also strengthened its Board by appointing Ramesh Ramadurai, Suchita Sharma and Shashank Sinha as Independent Directors. Initially, the business will continue leveraging its existing contract manufacturing partnerships while gradually building its own operational capabilities.

Management Focuses on Portfolio Expansion

Dr. Vikas Gupta, Chief Executive Officer and Managing Director, said the company intends to build on its decades-long legacy of scientific excellence and physician confidence. He noted that, with ChrysCapital’s support, the company now has the resources and strategic focus to expand its product portfolio, reach more patients and accelerate long-term growth while preserving the values that have defined the organisation over the years.

ChrysCapital Sees Long-Term Value Creation

Kshitij Sheth, Managing Director at ChrysCapital Advisors, said the company’s established brands, strong market reputation and trusted legacy provide a solid foundation for sustainable long-term value creation. He added that ChrysCapital will work closely with the management team to unlock new growth opportunities and strengthen the company’s position in India’s rapidly evolving pharmaceutical market.

New Chapter Begins for Novartis India

With new ownership, experienced leadership and a planned corporate rebranding, Novartis India is poised to begin a new chapter focused on expanding its branded generics business. As reported by thehindubusinessline.com, backed by ChrysCapital’s investment and strategic direction, the company aims to leverage its legacy brands while pursuing sustainable growth in one of the world’s fastest-growing pharmaceutical markets.

RPG Life Sciences Ltd (RPGLS) has announced a strategic restructuring of its Active Pharmaceutical Ingredients (API) business by transferring it to its wholly owned subsidiary, RPG Active Pharma Ltd (RPGAP). Simultaneously, the company has signed an agreement to acquire Actis Generics Private Ltd, an API manufacturing company based in Visakhapatnam, as part of its long-term growth strategy. The move is aimed at building a focused, scalable and globally competitive API business while strengthening the company’s position in India’s rapidly expanding pharmaceutical manufacturing sector.

API Business to Operate Through Dedicated Subsidiary

RPG Life Sciences has executed a Business Transfer Agreement to transfer its API business to RPG Active Pharma Ltd on a slump sale basis as a going concern. According to the company, the restructuring will enable dedicated capital allocation, sharper management focus and greater strategic flexibility for the API business, while allowing RPG Life Sciences to continue expanding its formulations business independently. The initiative also comes at a time when global pharmaceutical supply chains are undergoing structural changes, with India emerging as a preferred destination for reliable and high-quality API manufacturing.

InvAscent to Invest Up to ₹700 Crore

To support the expansion of its API business, RPG Active Pharma has entered into an investment agreement with InvAscent, a healthcare-focused private equity investor. Funds managed by InvAscent will make an initial investment of up to ₹243 crore in RPG Active Pharma. The agreement further provides for investments of up to ₹700 crore, jointly by RPG Life Sciences and InvAscent, in multiple phases. The capital infusion will be utilised to strengthen manufacturing infrastructure, expand the API product portfolio, enhance process development capabilities and pursue both organic and inorganic growth opportunities.

Actis Generics Acquisition to Expand Manufacturing Capacity

As part of its growth strategy, RPG Active Pharma has also signed a Share Purchase Agreement to acquire 100% equity in Actis Generics Private Ltd. The acquisition will significantly enhance RPG Active Pharma’s manufacturing capabilities while broadening its API portfolio and strengthening its ability to serve both domestic and international pharmaceutical customers. The company also indicated that it has been exploring opportunities to acquire additional manufacturing facilities for APIs or formulations, reflecting its continued focus on capacity expansion. The proposed transactions remain subject to customary regulatory approvals and the fulfilment of pre-closing conditions.

Management Confident About API Growth Strategy

Ashok Nair, Managing Director, RPG Life Sciences, said building a meaningful and scalable API business has been a strategic priority for the company. He noted that the creation of RPG Active Pharma provides a dedicated platform to accelerate growth with greater speed, operational discipline and scale. He added that the proposed acquisition of Actis Generics will further strengthen manufacturing capabilities, diversify the product portfolio and support the company’s objective of creating a high-quality API business that delivers long-term value to all stakeholders.

InvAscent Sees Strong Long-Term Potential

Dr. Jeevak Gupta, Managing Director, InvAscent, said RPG Active Pharma is well-positioned to capitalise on the growing global demand for high-quality API manufacturing. He expressed confidence that the partnership would help build a strong and competitive API platform capable of serving global pharmaceutical markets.

Strategic Move to Strengthen India’s API Manufacturing Ecosystem

As reported by thehindubusinessline.com, through the creation of RPG Active Pharma, the acquisition of Actis Generics and a planned investment of up to ₹700 crore, RPG Life Sciences is positioning itself for the next phase of growth in the API sector. The strategic initiatives are expected to strengthen manufacturing capabilities, expand product offerings and reinforce the company’s role in India’s evolving pharmaceutical supply chain.

Shivtek Spechemi Industries Ltd announced an investment of over ₹150 crore to establish a greenfield integrated specialty chemicals manufacturing complex at Pungam, Ankleshwar, Gujarat. Spread across approximately 21 acres, the facility will be developed in two phases and will add a total production capacity of 1,44,000 metric tonnes per annum (MTPA). The project will also serve as a platform for developing next-generation methanol-to-gas and hydrogen fuel technologies for the global shipping industry.

Facility to Strengthen Manufacturing Network

The Ankleshwar complex will enhance Shivtek Spechemi’s manufacturing footprint alongside its existing facilities at Kurnool, Rajpura and Dahej. Strategically located on the Delhi-Mumbai Expressway and close to Hazira Port, the site offers excellent connectivity to key freight corridors, raw material suppliers and export markets. In addition, the proposed Bhadbhut Barrage Project is expected to improve logistics connectivity with the company’s Dahej manufacturing unit, enabling greater operational efficiency.

Phase 1 to Commence by March 2027

The first phase of the project is scheduled for commissioning by March 2027 and will add a production capacity of 84,000 MTPA. This phase will manufacture pharma-grade Hydrochloric Acid (HCl), specialty feedstocks and specialty petrochemicals, strengthening the company’s presence in high-value chemical segments.

Phase 2 to Focus on Clean Energy Technologies

In the second phase, Shivtek Spechemi will add another 60,000 MTPA of production capacity while establishing pilot-scale facilities for Methanol-to-Gas and Hydrogen Fuel technologies. These initiatives are designed to support cleaner and more sustainable fuel solutions for the global maritime industry. At the same time, the company will expand its portfolio of petrochemical intermediates to address growing domestic and international demand.

Serving High-Growth Industrial Sectors

Once fully operational, the integrated manufacturing complex will supply specialty chemicals and high-value intermediates to a wide range of industries, including pharmaceuticals, agrochemicals, personal care, textiles, industrial coatings and water treatment. The project is also expected to generate substantial direct and indirect employment while adhering to international environmental, health and safety (EHS) standards.

Company Aligns Expansion with India’s Growth Vision

Amitt Nenwani, Managing Director, Shivtek Spechemi Industries Ltd, said the investment marks a significant milestone in the company’s growth journey and supports the Government of India’s Viksit Bharat @2047 and Atmanirbhar Bharat initiatives. He noted that the strategic location near the Delhi-Mumbai Expressway, Hazira Port and the company’s Dahej facility provides the infrastructure and connectivity required for efficient expansion. He further stated that the new manufacturing complex will not only broaden Shivtek Spechemi’s specialty chemicals portfolio but also enable the company to pioneer Methanol-to-Gas and Hydrogen Fuel technologies for the shipping industry, reinforcing its commitment to innovation, sustainability and cleaner energy solutions.

Expansion to Boost Specialty Chemicals and Sustainable Innovation

As reported by manufacturingtodayindia.com, with this ₹150 crore investment, Shivtek Spechemi aims to strengthen its position in India’s specialty chemicals sector while advancing sustainable manufacturing and clean energy technologies. The integrated Ankleshwar facility is expected to play a key role in supporting the company’s long-term growth strategy and enhancing India’s capabilities in specialty chemicals and next-generation fuels.